Journal of Antimicrobial Chemotherapy (2002) 49, 7-10
© 2002 The British Society for Antimicrobial Chemotherapy
Supplement |
Amphotericin B: spectrum and resistance
Mycology Unit, Women's and Children's Hospital, North Adelaide 5006, Australia
Abstract
Amphotericin B is a polyene macrolide antibiotic derived from the actinomycete Streptomyces nodosus. Of the 200 known polyene agents, amphotericin B is the only one with toxicities that are sufficiently limited to permit intravenous administration. All polyenes have a common mechanism of action in that they preferentially bind to ergosterol, the primary sterol in the fungal cell membrane. The consequence of this binding includes disruption of the osmotic integrity of the membrane, with leakage of intracellular potassium and magnesium, and also the disruption of oxidative enzymes in target cells. Amphotericin B has a relatively broad spectrum of action and is useful in treating cases of candidosis, cryptococcosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, coccidioidomycosis, aspergillosis, extracutaneous sporotrichosis and mucormycosis, and some cases of hyalohyphomycosis and phaeohyphomycosis. Resistance (MIC > 2 mg/L) tends to be species-dependent and emerges uncommonly and slowly in isolates from patients treated with amphotericin B. These include some individual strains of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae, which may acquire resistance during treatment. Some isolates of Scedosporium apiospermum, Fusarium spp. and Sporothrix schenckii also show primary resistance, whereas all strains of Scedosporium prolificans demonstrate resistance. The main problems associated with the use of conventional amphotericin B have always been due to its poor aqueous solubility and toxicity rather than antifungal resistance.
Notes
* Tel: 61-8-8161-6459; Fax: 61-8-8161-7589; E-mail: dellis{at}adelaide.edu.au
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Michallet and J. I. Ito Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation J. Clin. Oncol., July 10, 2009; 27(20): 3398 - 3409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. H. A. Ament, M. W. A. Hubben, P. E. Verweij, R. de Groot, A. Warris, J. P. Donnelly, J. v. t Wout, and J. L. Severens Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach J. Antimicrob. Chemother., August 1, 2007; 60(2): 385 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Hinrikson, S. F. Hurst, T. J. Lott, D. W. Warnock, and C. J. Morrison Assessment of Ribosomal Large-Subunit D1-D2, Internal Transcribed Spacer 1, and Internal Transcribed Spacer 2 Regions as Targets for Molecular Identification of Medically Important Aspergillus Species J. Clin. Microbiol., May 1, 2005; 43(5): 2092 - 2103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schaenman, D. B. DiGiulio, L. F. Mirels, N. M. McClenny, G. J. Berry, A. W. Fothergill, M. G. Rinaldi, and J. G. Montoya Scedosporium apiospermum Soft Tissue Infection Successfully Treated with Voriconazole: Potential Pitfalls in the Transition from Intravenous to Oral Therapy J. Clin. Microbiol., February 1, 2005; 43(2): 973 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Reeves, T. Murphy, P. Daly, and K. Kavanagh Amphotericin B enhances the synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary pathogen Aspergillus fumigatus J. Med. Microbiol., August 1, 2004; 53(8): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pourshafie, S. Morand, A. Virion, M. Rakotomanga, C. Dupuy, and P. M. Loiseau Cloning of S-Adenosyl-L-Methionine:C-24-{Delta}-Sterol-Methyltransferase (ERG6) from Leishmania donovani and Characterization of mRNAs in Wild-Type and Amphotericin B-Resistant Promastigotes Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2409 - 2414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. L. De Socio, M. Fiorio, and G. Stagni AmBisome administration for Candida albicans shunt infections J. Antimicrob. Chemother., December 1, 2003; 52(6): 1048 - 1049. [Full Text] [PDF]
|
|
|
|
|
|
K. Kummerer Significance of antibiotics in the environment J. Antimicrob. Chemother., July 1, 2003; 52(1): 5 - 7. [Full Text] [PDF]
|
|
|
|
|
|
T. Noel, F. Francois, P. Paumard, C. Chastin, D. Brethes, and J. Villard Flucytosine-Fluconazole Cross-Resistance in Purine-Cytosine Permease-Deficient Candida lusitaniae Clinical Isolates: Indirect Evidence of a Fluconazole Uptake Transporter Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1275 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, S. A. Messer, L. Boyken, and R. J. Hollis Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001 J. Clin. Microbiol., April 1, 2003; 41(4): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|